Evidence map›Paper›PMID 40911183›Full record

ArticleCurrent medical science2025

Differential Expression of ATP6V1D and Its Diagnostic Potential in IgA Nephropathy.

Liang Peng, Lin Hu, Yi-Qun Peng, Dong-Guang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liang PengDepartment of Nephrology, The Second Affiliated Hospital of the University of South China, Hengyang, 421001, China. 2023020144@usc.edu.cn.ORCID http://orcid.org/0009-0003-2158-771X
Lin HuDepartment of Nephrology, Loudi Central Hospital of Hunan Province, Loudi, 417000, China.
Yi-Qun PengDepartment of Nephrology, The Second Affiliated Hospital of the University of South China, Hengyang, 421001, China.
Dong-Guang WangDepartment of Agriculture and Biotechnology, Hunan University of Humanities, Science and Technology, Loudi, 417000, China.

Funding

the Health Commission of Hunan Province Scientific Research Projects 202203054127the Science and Technology Innovation Project of Hunan Province 2020SK51601Wellcome Trust 202202
6 · The paper itself

Abstract

objectiveIgA nephropathy (IgAN) is the most prevalent form of primary glomerular disease. However, its diagnosis is contingent on kidney biopsy. Therefore, noninvasive biomarkers are urgently needed for diagnosis. This study aims to identify novel urinary biomarkers that differentiate IgAN from other common primary glomerular diseases, specifically membranous nephropathy (MN) and minimal change disease (MCD).

methodsThe peripheral blood mononuclear cell (PBMC) transcriptome dataset GSE73953 was obtained from the GEO database. Differential gene expression, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, Gene Ontology (GO) enrichment, and immune infiltration analyses were performed. Protein-protein interaction (PPI) analysis and lysosome-related genes were used to identify hub genes. The expression of the hub gene ATP6V1D in urine and kidney tissues from individuals with IgAN, healthy controls, MCD and MN patients was assessed using enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunostaining techniques. Spearman's correlation analysis was employed to investigate the relationships between the concentration of ATP6V1D in urine, the concentration of galactose-deficient IgA1 (GD-IgA1), and the clinical data of patients. The receiver operating characteristic (ROC) curve was used to assess the role of urine ATP6V1D levels in distinguishing IgAN from MN and MCD.

resultsATPase was identified as the principal intracellular structure associated with differentially expressed genes (DEGs) between IgAN patients and healthy controls in PBMCs. ATP6V1D was identified as a hub gene at the intersection of lysosome-related and differential genes. ATP6V1D levels were lower in PBMCs, urine, and kidney samples from IgAN patients than in those from healthy individuals, MCD and MN patients. The decreased urinary ATP6V1D levels and increased GD-IgA1 levels in IgAN patients were further validated. These changes were positively correlated with 24-h urine protein levels. Notably, a negative correlation was observed between ATP6V1D and GD-IgA1 levels. ROC curve analysis demonstrated that urinary ATP6V1D (AUC = 0.972) and GD-IgA1 (AUC = 0.952) had significant discriminative power in distinguishing IgAN patients from MCD and MN patients, with no significant difference in predictive performance between the two biomarkers (P > 0.05).

conclusionsThe findings underscore the potential utility of the urine ATP6V1D concentration as a biomarker to distinguish IgAN from MN and MCD.

Indexed as

Glomerulonephritis, IGAVacuolar Proton-Translocating ATPasesAdultBiomarkersDiagnosis, DifferentialFemaleGlomerulonephritis, MembranousHumansLeukocytes, MononuclearMaleProtein Interaction MapsROC CurveTranscriptomeBiomarkersVacuolar Proton-Translocating ATPasesBiomarkerIgA nephropathyMembranous nephropathyMinimal change diseasePeripheral blood mononuclear cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.